Tags: Cancer | copycat | version | cancer | drug | herceptin

Copycat Version of Cancer Drug Herceptin Found Effective

Copycat Version of Cancer Drug Herceptin Found Effective
(Copyright AP)

Thursday, 21 July 2016 11:39 AM

Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

There were no "clinically meaningful" differences in data gathered from patients given Herceptin and the copycat version, ABP 980, to treat a type of early breast cancer, said Sean Harper, Amgen's executive vice president of research and development.

"... We believe that the totality of the evidence we've generated supports ABP 980 as highly similar to the reference product," he said.

Roche's Herceptin is an injected biologic drug made from living cells. Biologics are more complex than traditional pills and cannot be copied with precision, and so, their knock-off versions are called biosimilars instead of generics.

Herceptin, which generated sales of more than 6 billion Swiss francs last year, is also approved for use in forms of metastatic breast cancer and gastric cancer.

© 2021 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
Amgen Inc and Allergan Plcsaid their copycat version of Roche Holding AG'sblockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.There were no clinically meaningful differences in data gathered from patients given Herceptin...
copycat, version, cancer, drug, herceptin
151
2016-39-21
Thursday, 21 July 2016 11:39 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved